Daniel will be presenting some exciting data regarding NeuCyte's human neural in vitro platforms. Our SynFire technology allows us to plate fully defined neural cell based assays, consisting of Excitatory Glutamatergic neurons, Inhibitory GABAergic neurons and astroglia, which rapidly mature and become synaptically competent. This allows for the assessment of relevant electrophysiological readouts. Daniel's talk will focus on NeuCyte's optimized platform for predicting seizuregenic potential of novel drugs and AED validation.